bioMérieux Wins 2022 Food Safety Innovation Award

May 05, 2022

 

Company is Changing the Game of Food Safety and Quality by Bringing the Best Minds and the Best Science Together to Provide Compliant, Impactful Solutions for the Industry.

 

May 5, 2022, CHICAGO, IL —bioMérieux, a world leader in the field of in vitro diagnostics, has won the 2022 Food Safety Innovation Award for Predictive Diagnostics from the International Association for Food Protection (IAFP).

One of the inventors, Adam Joelsson, senior director of technology and R&D at Invisible Sentinel, a bioMérieux company, will accept this prestigious award for bioMérieux’s Predictive Diagnostics, which harnesses the full power of data to deliver relevant, actionable insights and custom diagnostic tools that enable better product quality, reduce risk, and increase profitability and efficiency.

“bioMérieux is honored to have Predictive Diagnostics recognized with the Food Safety Innovation Award from the International Association for Food Protection. We believe these tools will help the industry’s risk reduction approach continue its evolution from detect-and-respond towards proactive prevention through credible and actionable data,” said Joelsson.

Predictive Diagnostics is a game changer in the industry. Using customer data as a blueprint to predict and protect the customer’s future through identification and targeting of potential issues enables proactive prevention and brand protection, while also shielding manufacturers from liability and compliance concerns.

bioMérieux knows that no two facilities are alike and has designed Predictive Diagnostics to adapt to any existing product, process or facility. This allows for a collaborative and customizable approach to each individual Predictive Diagnostics customer. Scientific experts work closely with manufacturers to create comprehensive, customized, and efficient plans for minimizing financial and safety risk at every level of their organization.

“This prestigious award represents the hard work of the people behind the science,” says Miguel Villa, Senior Vice President, Industrial Microbiology, bioMérieux. “With Predictive Diagnostics, we are working together with the industry to solve the biggest problems through cutting-edge collaborative approaches. This signals a bold shift for the food safety and quality community and is changing the way we work as an industry.”

Predictive Diagnostics was developed through a team of global scientists focused on consumer safety and meeting industry needs by offering adaptable solutions with meaningful impact.  

What the industry is saying

"What is so innovative about this approach isn’t just the assays that were developed, it is the way that bioMérieux leverages Predictive Diagnostics to solve industry problems from an innovative forward-looking approach. They do not try to fit their solution to the industry need, instead it is the opposite; they ask the industry to bring their problems and collaborate together to build the best solutions. The result: more actionable data and a better understanding of how to prevent quality and safety issues before they impact our customers and our brand.” Patrick Bird, principal consultant, PMB BioTek Consulting, LLC. 

"bioMerieux’s utilization of predictive microbiology, genomics, and molecular biology has led to the development of tools that support risk-based decision making in the food industry. This team’s track record of high company standards and professionalism coupled with their long-standing participation in IAFP activities make them worthy recipients of this honor…in my experience of working with bioMérieux’s Predictive Diagnostics that they have been particularly successful in collaboration with industry and academia to develop technical innovations that fill particular voids and change thinking around sampling and testing.” Abigail B. Snyder, Ph.D., assistant professor of microbial food safety, Cornell University. 

For more information on Predictive Diagnostics, please visit www.predictive-diagnostics.com.

 

ABOUT BIOMÉRIEUX 

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 90% of sales outside of France.  

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: www.biomerieux.com.

 

CONTACTS

JUNIPR

Samantha Flynn 
+1 (717) 413-0370  
samantha@juniprcommunications.com 

 

bioMérieux

Maggie DiSantis​​​​​​
1 (331) 385-1332 
Maggie.Disantis@biomerieux.com